vTv Therapeutics Inc (VTVT) - Net Assets
Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has net assets worth $89.96 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($98.81 Million) and total liabilities ($8.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore VTVT total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $89.96 Million |
| % of Total Assets | 91.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | 323.31% |
| 10-Year Change | N/A |
| Growth Volatility | 310.04 |
vTv Therapeutics Inc - Net Assets Trend (2013–2025)
This chart illustrates how vTv Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of vTv Therapeutics Inc to evaluate the tangible quality of the company's equity base.
Annual Net Assets for vTv Therapeutics Inc (2013–2025)
The table below shows the annual net assets of vTv Therapeutics Inc from 2013 to 2025. For live valuation and market cap data, see vTv Therapeutics Inc (VTVT) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $64.44 Million | +350.58% |
| 2024-12-31 | $14.30 Million | +177.10% |
| 2023-12-31 | $-18.55 Million | -417.67% |
| 2022-12-31 | $5.84 Million | -61.64% |
| 2021-12-31 | $15.22 Million | +301.32% |
| 2020-12-31 | $3.79 Million | +142.91% |
| 2019-12-31 | $-8.84 Million | +89.33% |
| 2018-12-31 | $-82.85 Million | +45.15% |
| 2017-12-31 | $-151.05 Million | -66.09% |
| 2016-12-31 | $-90.94 Million | -16.64% |
| 2015-12-31 | $-77.97 Million | +84.37% |
| 2014-12-31 | $-498.81 Million | -64.23% |
| 2013-12-31 | $-303.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to vTv Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2295900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $39.00K | 0.06% |
| Other Components | $391.09 Million | 606.93% |
| Total Equity | $64.44 Million | 100.00% |
vTv Therapeutics Inc Competitors by Market Cap
The table below lists competitors of vTv Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhong Yang Technology Co Ltd
TW:6668
|
$119.97 Million |
|
Megaforce Co Ltd
TWO:3294
|
$119.99 Million |
|
Servotronics Inc
NYSE MKT:SVT
|
$120.00 Million |
|
Hanyang Digitech Co. Ltd
KQ:078350
|
$120.04 Million |
|
Torimbia Socimi S.A.
MC:YTRM
|
$119.94 Million |
|
Nelly Group AB
ST:NELLY
|
$119.93 Million |
|
enGene Holdings Inc. Common Stock
NASDAQ:ENGN
|
$119.91 Million |
|
Dongsung Corporation
KO:102260
|
$119.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in vTv Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,199,000 to 64,437,000, a change of 52,238,000 (428.2%).
- Net loss of 26,974,000 reduced equity.
- New share issuances of 77,476,000 increased equity.
- Other factors increased equity by 1,736,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.97 Million | -41.86% |
| Share Issuances | $77.48 Million | +120.24% |
| Other Changes | $1.74 Million | +2.69% |
| Total Change | $- | 428.22% |
Book Value vs Market Value Analysis
This analysis compares vTv Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.23x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-1478.08 | $32.35 | x |
| 2014-12-31 | $-2402.34 | $32.35 | x |
| 2015-12-31 | $-9.42 | $32.35 | x |
| 2016-12-31 | $-9.53 | $32.35 | x |
| 2017-12-31 | $-623.31 | $32.35 | x |
| 2018-12-31 | $-266.21 | $32.35 | x |
| 2019-12-31 | $-64.73 | $32.35 | x |
| 2020-12-31 | $-67.97 | $32.35 | x |
| 2021-12-31 | $-6.22 | $32.35 | x |
| 2022-12-31 | $-5.59 | $32.35 | x |
| 2023-12-31 | $-11.84 | $32.35 | x |
| 2024-12-31 | $2.11 | $32.35 | x |
| 2025-12-31 | $7.65 | $32.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently vTv Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-41.86%) is below the historical average (-14.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -4938.83% | 0.06x | 0.00x | $-17.83 Million |
| 2014 | 0.00% | -2330.60% | 0.12x | 0.00x | $13.78 Million |
| 2015 | 0.00% | -5298.27% | 0.01x | 0.00x | $-19.70 Million |
| 2016 | 0.00% | -2579.18% | 0.01x | 0.00x | $-7.26 Million |
| 2017 | 0.00% | -5547.77% | 0.01x | 0.00x | $-1.04 Million |
| 2018 | 0.00% | -63.62% | 1.45x | 0.00x | $374.30K |
| 2019 | 0.00% | -793.70% | 0.30x | 0.00x | $-17.04 Million |
| 2020 | 0.00% | -132.51% | 0.43x | 0.00x | $-488.80K |
| 2021 | 0.00% | -324.27% | 0.16x | 0.00x | $-12.01 Million |
| 2022 | 0.00% | -949.65% | 0.06x | 0.00x | $-18.09 Million |
| 2023 | 0.00% | -225000.00% | 0.00x | 0.00x | $-17.78 Million |
| 2024 | -151.34% | -1815.34% | 0.03x | 3.14x | $-19.68 Million |
| 2025 | -41.86% | 0.00% | 0.00x | 1.40x | $-33.42 Million |
Industry Comparison
This section compares vTv Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| vTv Therapeutics Inc (VTVT) | $89.96 Million | 0.00% | 0.10x | $119.97 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more